The Sodium Reduction Strategy for Canada includes an identification of priority areas for future research, based on a workshop convened by the Canadian Institutes of Health Research (CIHR) and partners. A strong portfolio of research is essential to addressing current developments and controversies raised in relation to the health outcomes associated with dietary sodium. CIHR aims to provide leadership in working together with other funders and partners to catalyze a broad range of sodium research.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1139/apnm-2013-0370 | DOI Listing |
Expert Rev Endocrinol Metab
January 2025
College of Medicine & Health Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are known for their cardiovascular benefits, but their impact on serum uric acid levels is not well understood. This study evaluates the hypouricemic effects of SGLT2is and their potential cardiovascular implications.
Methods: A network meta-analysis was performed, including 56 studies (16,788 participants) contributing data to the meta-analysis.
FASEB J
January 2025
Department of Anatomy, Korea University College of Medicine, Seoul, Republic of Korea.
Sarcopenia is an age-related muscle atrophy syndrome characterized by the loss of muscle strength and mass. Although many agents have been used to treat sarcopenia, there are no successful treatments to date. In this study, we identified Danshensu sodium salt (DSS) as a substantial suppressive agent of muscle atrophy.
View Article and Find Full Text PDFEndocr Metab Immune Disord Drug Targets
January 2025
Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, China.
Background: Heart failure with preserved ejection fraction (HFpEF) represents a challenging cardiovascular condition characterized by normal systolic function but impaired diastolic performance. Despite its increasing prevalence, therapeutic options remain limited. This study investigated the metabolic effects of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on cardiac function and energy metabolism in HFpEF.
View Article and Find Full Text PDFLancet Reg Health Am
February 2025
National Institute of Science and Technology for Health Technology Assessment, Porto Alegre, Brazil.
Background: Heart failure, a complex clinical syndrome with high morbidity and mortality, has become a significant burden on public health. Recently, a new class of antidiabetic agents-the sodium-glucose cotransporter 2 (SGLT2) inhibitors-was associated with a significant reduction on mortality and hospitalization in HF with reduced ejection fraction (HFrEF) when added to standard pharmacological treatment. Considering the lack of data on its cost-effectiveness, the present study aims to estimate the incremental cost-effectiveness ratio of add-on dapagliflozin treatment for HFrEF from the Brazilian public healthcare system perspective.
View Article and Find Full Text PDFCureus
December 2024
Diabetes Research Group, Swansea University Medical School, Swansea, GBR.
Introduction Type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) have shared pathophysiology. We aim to explore associations between these diseases and the impact of T2D therapies on MASLD-related outcomes in a real-world population. Methods A retrospective cohort study included 153 patients with biopsy-proven MASLD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!